Dongwha Pharm.Co.Ltd Past Earnings Performance
Past criteria checks 4/6
Dongwha Pharm.Co.Ltd has been growing earnings at an average annual rate of 20.8%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 4.1% per year. Dongwha Pharm.Co.Ltd's return on equity is 6.9%, and it has net margins of 7.6%.
Key information
20.8%
Earnings growth rate
20.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 4.1% |
| Return on equity | 6.9% |
| Net Margin | 7.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26
We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Recent updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?
Apr 28These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely
Mar 11Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%
Feb 22Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?
Feb 07Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?
Jan 23Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?
Jan 08
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days
Dec 24We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?
Dec 04Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?
Nov 19Revenue & Expenses BreakdownBeta
How Dongwha Pharm.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 361,109 | 27,438 | 143,565 | 21,548 |
| 30 Sep 23 | 361,326 | 29,155 | 138,920 | 20,313 |
| 30 Jun 23 | 357,324 | 29,177 | 132,526 | 20,772 |
| 31 Mar 23 | 354,552 | 27,685 | 129,165 | 20,524 |
| 31 Dec 22 | 340,426 | 20,383 | 125,774 | 19,285 |
| 30 Sep 22 | 332,285 | 22,907 | 126,486 | 8,965 |
| 30 Jun 22 | 317,901 | 17,410 | 118,876 | 11,463 |
| 31 Mar 22 | 306,485 | 17,660 | 108,251 | 17,336 |
| 31 Dec 21 | 293,018 | 17,870 | 103,215 | 17,338 |
| 30 Sep 21 | 285,371 | 19,928 | 98,998 | 17,459 |
| 30 Jun 21 | 282,868 | 31,238 | 95,832 | 17,377 |
| 31 Mar 21 | 276,899 | 31,693 | 93,364 | 17,383 |
| 31 Dec 20 | 272,075 | 28,508 | 92,558 | 16,912 |
| 30 Sep 20 | 286,746 | 28,405 | 89,901 | 17,156 |
| 30 Jun 20 | 294,395 | 16,884 | 90,649 | 16,987 |
| 31 Mar 20 | 299,490 | 9,533 | 91,424 | 16,581 |
| 31 Dec 19 | 307,150 | 9,116 | 90,636 | 16,332 |
| 30 Sep 19 | 299,195 | 4,881 | 91,613 | 16,408 |
| 30 Jun 19 | 299,893 | 5,823 | 90,683 | 16,183 |
| 31 Mar 19 | 304,302 | 7,202 | 89,285 | 15,781 |
| 31 Dec 18 | 306,603 | 10,069 | 85,519 | 15,605 |
| 31 Dec 17 | 258,882 | 47,009 | 79,450 | 14,078 |
| 30 Sep 13 | 223,402 | -5,700 | 92,118 | 0 |
| 30 Jun 13 | 224,831 | 2,339 | 89,470 | 0 |
Quality Earnings: A000020 has a large one-off gain of ₩9.0B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A000020's current net profit margins (7.6%) are higher than last year (6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A000020's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: A000020's earnings growth over the past year (34.6%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: A000020 earnings growth over the past year (34.6%) exceeded the Pharmaceuticals industry 34.6%.
Return on Equity
High ROE: A000020's Return on Equity (6.9%) is considered low.